These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 7819590)

  • 1. Targeting the EGF receptor in breast cancer treatment.
    LeMaistre CF; Meneghetti C; Howes L; Osborne CK
    Breast Cancer Res Treat; 1994; 32(1):97-103. PubMed ID: 7819590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the epidermal growth factor receptor in breast cancer cell lines with a recombinant ligand fusion toxin (DAB389EGF).
    Osborne CK; Coronado-Heinsohn E
    Cancer J Sci Am; 1996; 2(3):175-80. PubMed ID: 9166518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytotoxic properties of DAB486EGF and DAB389EGF, epidermal growth factor (EGF) receptor-targeted fusion toxins.
    Shaw JP; Akiyoshi DE; Arrigo DA; Rhoad AE; Sullivan B; Thomas J; Genbauffe FS; Bacha P; Nichols JC
    J Biol Chem; 1991 Nov; 266(31):21118-24. PubMed ID: 1939154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of epidermal growth factor receptor and STAT-3 activation in autonomous proliferation of SUM-102PT human breast cancer cells.
    Sartor CI; Dziubinski ML; Yu CL; Jove R; Ethier SP
    Cancer Res; 1997 Mar; 57(5):978-87. PubMed ID: 9041204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting tumor cells via EGF receptors: selective toxicity of an HBEGF-toxin fusion protein.
    Chandler LA; Sosnowski BA; McDonald JR; Price JE; Aukerman SL; Baird A; Pierce GF; Houston LL
    Int J Cancer; 1998 Sep; 78(1):106-11. PubMed ID: 9724101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotoxins in cancer therapy: Review and update.
    Akbari B; Farajnia S; Ahdi Khosroshahi S; Safari F; Yousefi M; Dariushnejad H; Rahbarnia L
    Int Rev Immunol; 2017 Jul; 36(4):207-219. PubMed ID: 28282218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DAB389EGF fusion protein therapy of refractory glioblastoma multiforme.
    Cohen KA; Liu T; Bissonette R; Puri RK; Frankel AE
    Curr Pharm Biotechnol; 2003 Feb; 4(1):39-49. PubMed ID: 12570681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination fusion protein therapy of refractory brain tumors: demonstration of efficacy in cell culture.
    Liu TF; Cohen KA; Willingham MC; Tatter SB; Puri RK; Frankel AE
    J Neurooncol; 2003 Oct; 65(1):77-85. PubMed ID: 14649887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy.
    Mathew M; Verma RS
    Cancer Sci; 2009 Aug; 100(8):1359-65. PubMed ID: 19459847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant heregulin-Pseudomonas exotoxin fusion proteins: interactions with the heregulin receptors and antitumor activity in vivo.
    Yang D; Kuan CT; Payne J; Kihara A; Murray A; Wang LM; Alimandi M; Pierce JH; Pastan I; Lippman ME
    Clin Cancer Res; 1998 Apr; 4(4):993-1004. PubMed ID: 9563895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapy of cancer using diphtheria toxin-derived immunotoxins.
    Potala S; Sahoo SK; Verma RS
    Drug Discov Today; 2008 Sep; 13(17-18):807-15. PubMed ID: 18678276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diphtheria toxin-epidermal growth factor fusion protein DAB389EGF for the treatment of bladder cancer.
    Yang X; Kessler E; Su LJ; Thorburn A; Frankel AE; Li Y; La Rosa FG; Shen J; Li CY; Varella-Garcia M; Glodé LM; Flaig TW
    Clin Cancer Res; 2013 Jan; 19(1):148-57. PubMed ID: 23172881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The epidermal growth factor receptor as a target for therapy in breast carcinoma.
    Baselga J; Mendelsohn J
    Breast Cancer Res Treat; 1994 Jan; 29(1):127-38. PubMed ID: 8018961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted toxins as anticancer agents.
    Siegall CB
    Cancer; 1994 Aug; 74(3 Suppl):1006-12. PubMed ID: 7913661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor-dependent cytotoxic effect by an EGF-ribonuclease conjugate on human cancer cell lines--a trial for less immunogenic chimeric toxin.
    Jinno H; Ueda M; Ozawa S; Kikuchi K; Ikeda T; Enomoto K; Kitajima M
    Cancer Chemother Pharmacol; 1996; 38(4):303-8. PubMed ID: 8674151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel reduced immunogenicity bispecific targeted toxin simultaneously recognizing human epidermal growth factor and interleukin-4 receptors in a mouse model of metastatic breast carcinoma.
    Oh S; Stish BJ; Sachdev D; Chen H; Dudek AZ; Vallera DA
    Clin Cancer Res; 2009 Oct; 15(19):6137-47. PubMed ID: 19789305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted tumor therapy by epidermal growth factor appended toxin and purified saponin: an evaluation of toxicity and therapeutic potential in syngeneic tumor bearing mice.
    Thakur M; Mergel K; Weng A; von Mallinckrodt B; Gilabert-Oriol R; Dürkop H; Melzig MF; Fuchs H
    Mol Oncol; 2013 Jun; 7(3):475-83. PubMed ID: 23298730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant toxin DAB389EGF is cytotoxic to human pancreatic cancer cells.
    Mishra G; Liu TF; Frankel AE
    Expert Opin Biol Ther; 2003 Oct; 3(7):1173-80. PubMed ID: 14519080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermal growth factor receptors and EGF-responsiveness of the human breast-carcinoma cell line PMC42.
    Monaghan P; Ormerod MG; O'Hare MJ
    Int J Cancer; 1990 Nov; 46(5):935-43. PubMed ID: 2228321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interstitial diphtheria toxin-epidermal growth factor fusion protein therapy produces regressions of subcutaneous human glioblastoma multiforme tumors in athymic nude mice.
    Liu TF; Hall PD; Cohen KA; Willingham MC; Cai J; Thorburn A; Frankel AE
    Clin Cancer Res; 2005 Jan; 11(1):329-34. PubMed ID: 15671563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.